Pharming Group (PHAR) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts4

Ratings

Updated Sep 12, 2026

Overall Rating

B

DCF Score5.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score4.0 / 5

ROE Score3.0 / 5

Valuation

Current Stock Price

$11.21

Median Target+247.90%

$39.00

Potential upside vs current price

DCF Value+22.09%

$13.69

Potential upside vs current price

Current Stock Price

$11.21

Median Target+247.90%

$39.00

Potential upside vs current price

DCF Value+22.09%

$13.69

Potential upside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts4

Ratings

Updated Sep 12, 2026

Overall Rating

B

DCF Score5.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score4.0 / 5

ROE Score3.0 / 5

Valuation

Current Stock Price

$11.21

Median Target+247.90%

$39.00

Potential upside vs current price

DCF Value+22.09%

$13.69

Potential upside vs current price

Current Stock Price

$11.21

Median Target+247.90%

$39.00

Potential upside vs current price

DCF Value+22.09%

$13.69

Potential upside vs current price

Pharming Group N.V.